Back to search results
NCT04884035

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Active, Not Recruiting
PHASE1Ages 18+InterventionalTreatment
Celgene
~224 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:CC-220RituximabCyclophosphamideDoxorubicinVincristinePrednisone

At a glance

Recruiting sites
0 of 36 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Tolerated Dose (MTD) - Part 1
Measured over During the first 2 cycles of treatment (each cycle is 21 days)
+4 more outcomes measured

Conditions

Lymphoma, B-Cell

Explore related trials

B-Cell Non-Hodgkin Lymphoma

NCT04884035

Where you'd take part

This study runs at 36 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Local Institution - 151

    Omaha, Nebraskano site contact published

  • Local Institution - 152

    Rochester, Minnesotano site contact published

  • Local Institution - 154

    Scottsdale, Arizonano site contact published

  • Local Institution - 155

    Houston, Texasno site contact published

  • Local Institution - 159

    Kansas City, Kansasno site contact published

  • Local Institution - 160

    Jacksonville, Floridano site contact published

  • Local Institution - 161

    Marietta, Georgiano site contact published

  • Local Institution - 162

    Birmingham, Alabamano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must satisfy the following criteria to be enrolled in the study:

Exclusion

The presence of any of the following will exclude a participant from enrollment:

What this trial measures

  • Maximum Tolerated Dose (MTD) - Part 1During the first 2 cycles of treatment (each cycle is 21 days)

    Frequency of dose-limiting toxicities (DLT) associated with addition of iberdomide (CC-220) to R-CHOP-21 therapy and the addition of CC-99282 to R-CHOP-21 therapy

  • Recommended Phase 2 Dose (RP2D) - Part 1During the first cycle of treatment (each cycle is 21 days)

    Defined as the dose that will be selected for dose expansion based on MTD

  • Safety and tolerability of CC-220 and CC-99282 at RP2D - Part 2From the first dose of any IP until 28 days after the last dose of IP

    AEs evaluated using NCI CTCAE criteria, v. 5.0, including treatment -emergent adverse events (TEAEs) and laboratory assessments

  • Maximum Tolerated Dose (MTD) - Part 2ADuring the first cycle of treatment (each cycle is 21 days)

    Frequency of DLTs associated with addition of iberdomide (CC-220) to polatuzumab-R-CHP therapy and the addition of CC-99282 to polatuzumab-R-CHP therapy

  • Recommended Phase 2 Dose (RP2D) - Part 2ADuring the first cycle of treatment (each cycle is 21 days)

    Defined as the dose that will be selected for dose expansion based on MTD